MIRA INFORM REPORT
|
Report Date : |
14.01.2011 |
IDENTIFICATION DETAILS
|
Name : |
CADILA PHARMACEUTICALS LIMITED |
|
|
|
|
Formerly Known As : |
NOVA BIOSTIC INDIA PRIVATE LIMITED |
|
|
|
|
Registered Office : |
Cadila Corporate Campus, Sarkhej
- |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2010 |
|
|
|
|
Date of Incorporation : |
28.02.1991 |
|
|
|
|
Com. Reg. No.: |
04-015132 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24231GJ1991PLC015132 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
AHMC0038ID |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAACC6251E |
|
|
|
|
Legal Form : |
A Closely held Public Limited Liability
Company |
|
|
|
|
Line of Business : |
Manufacturer of Pharmaceutical
Products. |
RATING & COMMENTS
|
MIRA’s Rating : |
A (64) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 8500000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established and a reputed company having fine track.
Financial position of the company appears to be sound. Trade relations are reported
as fair. Business is active. Payments are reported to be regular and as per
commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – April 1, 2010
|
Country Name |
Previous Rating (31.12.2009) |
Current Rating (01.04.2010) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INFORMATION DENIED BY
|
Name : |
Mr. Vargis |
|
Designation : |
DGM – Finance |
|
Contact No.: |
91-2718-225001 |
|
Date : |
13.01.2011 |
LOCATIONS
|
Registered Office/ Corporate
Office : |
Cadila Corporate Campus, Sarkhej
- |
|
Tel. No.: |
91-2718-225001 (15 Lines) |
|
Fax No.: |
91-2718-225039 |
|
E-Mail : |
secretarial@cadilapharma.co.in purchase@cadilapharma.com,(For
Material Details), |
|
Website: |
|
|
Area : |
44 acres (Owned) |
|
|
|
|
Branch Office : |
IRMA House, Off |
|
Tel. No.: |
91-79-26562615 (5 lines) |
|
Fax No.: |
91-79-26425741 |
|
E-Mail : |
tc1@wilnetonline.net, info@cadilapharma.com,purchase@cadilapharma.com branded@cadilapharma.com,international@cadilapharma.com,info@cadilapharma.com |
|
Website : |
|
|
Area : |
5000 sq. ft. (Owned) |
|
|
|
|
Factory 1: |
IRMA House, Off |
|
Tel. No: |
91-79-6562615 (5 lines) |
|
Fax No: |
91-79-6425741 |
|
Area: |
5000 sq. ft. (Owned) |
|
|
|
|
Factory 2: |
Dholka – Manufacturing Plant Survey No. 1389, |
|
Tel. No: |
91-79-23421841/83/84/3422006/7/8/9/10 |
|
Fax No: |
91-79-23420315/3421220 |
|
Area: |
50000 sq. ft. (Owned ) |
|
|
|
|
Factory 3: |
Ankleshwar (Unit I) 294, GIDC Estate, Ankleshwar, Ankleshwar (Unit II) 3205, GIDC Estate, Ankleshwar, Industrial Growth Centre, Samba
– 184 121, District |
|
|
|
|
Factory 4: |
Tissu Culture Lab 756, Prakruti
Farm, Hirapur Chowkdi, Hirapur, Ahmedabad, |
|
Tel. No: |
91-79-3855260/3855495/496 |
|
Area: |
Owned |
|
|
|
|
Factory 5: |
Chemicals SBU – Factory Plot No. 274, GIDC Industrial
Estate, Ankleshwar, |
|
Tel. No: |
91-2646-223846 / 252626 / 251519 |
|
Fax No: |
91-2646-250051 |
|
Area: |
174557 sq. ft. (owned) |
|
|
|
|
Factory 6: |
CHPL – Factory (Associated
Company) Survey No. 342, Nani Kadi, Taluka Kadi, District Mehsana, North Gujarat, |
|
Tel. No: |
91-2764-262463 / 242037 / 242194 |
|
Fax No: |
91-2764-242223 |
|
Area: |
Owned |
|
|
|
|
Factory 7: |
Survey No. 342, Nani Kadi,
Taluka Kadi, District Mehsana, North Gujarat, |
|
Tel. No: |
91-2764-262463 / 242037 / 242194 |
|
Fax No: |
91-2764-242608 |
|
Area: |
Owned |
|
|
|
|
Branches: |
Located at: Ř
Mumbai Ř
|
DIRECTORS
As on 29.09.2010
|
Name : |
Mr. Indravadan Ambalal Modi |
|
Designation : |
Chairman and Managing Director |
|
Address : |
"KAKABA", 13, |
|
Date of Birth/Age : |
18.02.1926 |
|
Qualification : |
B. Sc. (Technical), Ph.D.
(Biology), Chemical Engineer from |
|
Experience : |
50 years |
|
Date of Appointment : |
27.05.1995 |
|
Other Directorships:- |
1. Casil Health Products Limited - Chairman 2. Karnavati Engineering Limited – Chairman 3. Indian Research Manifestation Laboratories (Private)
Limited (IRM Lab) – Chairman 4. Green Challel
Travel Services – Director 5. IRM Investment Private Limited – Trustee 6. IRM Trust |
|
|
|
|
Name : |
Dr. Rajiv Indravadan Modi |
|
Designation : |
Managing Director |
|
Address : |
13, |
|
Date of Birth/Age : |
09.05.1960 |
|
Qualification : |
Ph. D. in
Biological Science |
|
Date of Appointment : |
28.02.1991 |
|
Other Directorships:- |
·
Casil Health Products Limited, Ahmedabad, ·
Karnavati Engineering Limited, Ahmedabad, ·
Tissue Culture Laboratories, Ahmedabad, ·
Green Channel Travel Services Private
Limited |
|
|
|
|
Name : |
Mr. Atul Bipinbhai Tandon |
|
Designation : |
Director |
|
Address : |
Directors Bungalow, Mica, Shela,
Ahmedabad – 380058, |
|
Date of Birth/Age : |
03.01.1948 |
|
Date of Appointment : |
04.07.2003 |
|
|
|
|
Name : |
Mr. Daya Nand Khurana |
|
Designation : |
Director |
|
Address : |
288, Vasant Enclave, Vasant
Vihar, |
|
Date of Birth/Age : |
15.05.1935 |
|
Date of Appointment : |
04.07.2003 |
|
|
|
|
Name : |
Mrs. Monika Garware Modi |
|
Designation : |
Director |
|
Address : |
13, |
|
Date of Birth/Age : |
04.06.1963 |
|
Date of Appointment : |
16.12.1995 |
|
|
|
|
Name : |
Mr. Chinubhai Ramanlal Shah |
|
Designation : |
Director |
|
Address : |
402, Heritage Cresent, |
|
Date of Birth/Age : |
04.06.1937 |
|
Date of Appointment : |
31.03.2001 |
|
Other Directorships:- |
|
|
|
|
|
Name : |
Mr. Pradip Navin Khandwalla |
|
Designation : |
Director |
|
Address : |
B/101, |
|
Date of Birth/Age : |
18.02.1940 |
|
Date of Appointment : |
14.09.2007 |
|
|
|
|
Name : |
Mrs. Shilaben Indravadan Modi |
|
Designation : |
Director |
|
Address : |
13, Sanjiv Baug, New |
|
Date of Birth/Age : |
09.12.1931 |
|
Qualification : |
Matriculate |
|
Date of Appointment : |
16.12.1995 |
|
Other Directorships:- |
|
KEY EXECUTIVES
|
Name : |
Mr. Shreyas Kunjvuhari Parikh |
|
Designation : |
Secretary |
|
Address : |
B 001, Aakasheep Anne, Near
Shreyas Railway Crossing, Amba Wadi, Ahmedabad – 380 006, |
|
Date of Birth/Age : |
12.08.1957 |
|
Date of Appointment : |
22.02.2008 |
|
|
|
|
Name : |
Mr. Vargis |
|
Designation : |
DGM – Finance |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 29.09.2010
|
Names of Shareholders |
|
No. of Shares |
|
Indravadan A Modi |
|
7999990 |
|
Shilaben I Modi |
|
7999990 |
|
Indravadan A Modi (Trustee of
IRM Trust) |
|
59460955 |
|
Indravadan A. Modi (Karta of |
|
4525712 |
|
Shilaben I Modi (Trustee of IRM
Trust) |
|
13333 |
|
Rajiv I Modi (Trustee of IRM
Trust) |
|
10 |
|
Indravadan A. Modi (Trustee of Mansi
Trust) |
|
10 |
|
|
|
|
|
Total |
|
80000000 |
As on 29.09.2010
|
Equity Share Breakup |
|
Percentage of Holding |
|
Category |
|
|
|
Bodies
corporate |
|
80.00 |
|
Directors
or relatives of directors |
|
20.00 |
|
Total |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical
Products. |
||||||||
|
|
|
||||||||
|
Products : |
|
PRODUCTION STATUS (AS ON 31.03.2010)
|
Particulars |
|
Unit |
Installed
Capacity |
Actual
Production |
|
Tablets |
|
ML. Nos |
14913.000 |
4553.69 |
|
Capsules |
|
ML. Nos |
1124.00 |
246.36 |
|
Injections |
|
K. Litres |
297.67 |
168.63 |
|
Liquids |
|
K. Litres |
10376.00 |
1704.09 |
|
Ophthalmic |
|
K. Litres |
Nil |
10.27 |
|
Ointment |
|
Tonnes |
Nil |
7.76 |
|
Dry powder injections |
|
Tonnes |
9.79 |
4.63 |
|
Granules and dry syrups |
|
Tonnes |
220.17 |
85.03 |
|
Bulk drugs |
|
M.T |
934.96 |
896.18 |
|
Tissue cultures |
|
ML. Nos |
10.00 |
9.07 |
Notes:
- As the Industrial licensing in respect of Drugs and Pharmaceuticals
produced by the company has been waived, the particulars of licensed
capacity are not stated.
- The installed capacity is taken on 2 shift working as certified by
the management.
- Production includes production under loan license arrangement.
GENERAL INFORMATION
|
No. of Employees : |
Information not divulged by
management |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Bankers : |
Ř
Central Bank of Ř
Bank of Ř
Dena Bank Ř
State Bank of
Saurashtra Ř
Tamilnadu
Mercantile Co-operative Bank Limited Ř
Vijaya Bank Ř
Bank of Ř
Corporation Bank,
Avrangpura Branch, Ahmedabad, Ř
Oriental Bank of
Commerce, Ř
Punjab National
Bank, Ř
Union Bank of Ř
Axis Bank Limited,
Ahmedabad, Ř
Syndicate Bank, Ř
ICICI Bank, Bandra,
Mumbai, Ř
Canara Bank, Bhadra
Branch, Ahmedabad - 380001 Ř
Export Import Bank
of Ř
State Bank of Ř
Allahabad Bank, Ř
State Bank of Ř
HDFC Bank Limited,
HDFC Bank House Senapati Bapat Marg, Lower Parel West, Mumbai – 400013, Ř
The Karnataka Bank
Limited, Shree Gantha Karna Mahavee Complex, Near New Cloth Market,
Sarangpura, Ahmedabad-380002, |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Facilities : |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Deloitte Haskins and Sells Chartered Accountants |
|
Address : |
3rd Floor,
‘Heritage’, Near Gujarat Vidhyapith, Off |
|
Tel. No.: |
91-79-7582542/7582543/66073100 |
|
Fax No.: |
91-79-7582551 |
|
Pan No.: |
AABFD7919A |
|
E-Mail : |
|
|
|
|
|
Associates : |
|
|
|
|
|
Subsidiaries : |
|
|
|
|
|
Enterprises significantly influenced by Directors and / or their relatives
: |
|
CAPITAL STRUCTURE
As on 29.09.2010
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
80000000 |
Equity Shares |
Rs.10/- each |
Rs.800.000 Millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
80000000 |
Equity Shares |
Rs.10/- each |
Rs.800.000 Millions |
Note:
Out of the above 14884423 equity shares were
issued pursuant to scheme of arrangement and amalgamation, without payment
received in cash
15000000 equity shares of Rs. 10/- each fully paid
up, issued as bonus shares
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
800.000 |
800.000 |
450.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
1332.124 |
1314.395 |
1176.147 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
2132.124 |
2114.395 |
1626.147 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
3754.357 |
3704.106 |
2851.174 |
|
|
2] Unsecured Loans |
697.619 |
1064.987 |
612.381 |
|
|
TOTAL BORROWING |
4451.976 |
4769.093 |
3463.555 |
|
|
DEFERRED TAX LIABILITIES |
462.131 |
458.700 |
437.668 |
|
|
|
|
|
|
|
|
TOTAL |
7046.231 |
7342.188 |
5527.370 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
3382.072 |
2964.291 |
3037.358 |
|
|
Capital work-in-progress |
102.844 |
559.541 |
264.504 |
|
|
|
|
|
|
|
|
INVESTMENT |
1138.500 |
702.230 |
652.230 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
1148.883
|
1285.725 |
1081.721 |
|
|
Sundry Debtors |
1601.648
|
1791.952 |
1237.433 |
|
|
Cash & Bank Balances |
274.876
|
223.547 |
54.250 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
894.005
|
1669.952 |
881.173 |
|
Total
Current Assets |
3919.412
|
4971.176 |
3254.577 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
951.615
|
1333.024 |
1071.036 |
|
|
Other Current Liabilities |
493.928
|
390.744 |
500.402 |
|
|
Provisions |
51.054
|
131.282 |
109.861 |
|
Total
Current Liabilities |
1496.597
|
1855.050 |
1681.299 |
|
|
Net Current Assets |
2422.815
|
3116.126 |
1573.278 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
7046.231 |
7342.188 |
5527.370 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
6478.223 |
6538.342 |
5366.437 |
|
|
|
Other Income |
250.545 |
374.466 |
399.249 |
|
|
|
TOTAL (A) |
6728.768 |
6912.808 |
5765.686 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Purchase of Finished Goods |
561.468 |
745.182 |
514.763 |
|
|
|
Cost of Material Consumed |
2076.564 |
2401.799 |
1809.023 |
|
|
|
Manufacturing Expenses |
511.167 |
545.383 |
443.420 |
|
|
|
Personnel Expenses |
946.280 |
922.267 |
783.419 |
|
|
|
Administrative, Selling and
Distribution Expenses |
1253.231 |
1151.375 |
1029.427 |
|
|
|
Research and Development
Expenses |
275.070 |
269.433 |
212.494 |
|
|
|
Exceptional items |
295.861 |
212.328 |
0.000 |
|
|
|
Increase or Decrease in Stock |
136.433 |
(262.982) |
99.689 |
|
|
|
TOTAL (B) |
6056.074 |
5984.785 |
4892.235 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
672.694 |
928.023 |
873.451 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
424.465 |
405.645 |
286.923 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
248.229 |
522.378 |
586.528 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
221.698 |
218.763 |
212.319 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
26.531 |
303.615 |
374.209 |
|
|
|
|
|
|
|
|
|
Less |
TAX (I) |
8.802 |
82.429 |
107.425 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-I) (J) |
17.729 |
221.186 |
266.784 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
1160.044 |
1027.796 |
851.543 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
|
|
Transfer to General Reserve |
0.000 |
6.000 |
20.000 |
|
|
|
Dividend |
0.000 |
70.890 |
60.327 |
|
|
|
Tax on Dividend |
0.000 |
12.048 |
10.204 |
|
|
BALANCE CARRIED
TO THE B/S |
1177.773 |
1160.044 |
1027.796 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
149.845 |
220.658 |
NA |
|
|
|
Research material |
3.306 |
4.176 |
NA |
|
|
|
Stores and spares |
4.335 |
16.196 |
|
|
|
|
Capital goods |
116.428 |
181.495 |
|
|
|
|
Packing material |
1.173 |
3.402 |
NA |
|
|
TOTAL IMPORTS |
275.087 |
425.927 |
|
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
0.22 |
3.12 |
6.64 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
PAT / Total Income |
(%) |
0.26
|
3.20 |
4.63 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
0.41
|
4.64 |
6.97 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
0.36
|
3.83 |
5.95 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.01
|
0.14 |
0.23 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
2.79
|
3.13 |
3.16 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.62
|
2.68 |
1.94 |
LOCAL AGENCY FURTHER INFORMATION
The details of sundry
creditors:
Rs.
In Millions
|
Particulars |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
Sundry Creditors |
951.615
|
1333.024 |
1071.036 |
Contingent
Liabilities not provided for in respect of:
Rs.
In Millions
|
|
Particulars |
31.03.2010 |
|
a) |
In respect of guarantees given by a Bank and counter guarantee given
by the company |
501.092 |
|
b) |
Estimated amount of contracts remaining to be executed on capital
account and not provided for |
93.680 |
|
c) |
In respect of the demand raised by the ministry of chemical and
fertilizer, Government of India and disputed by the company based on the
legal advice |
14.242 |
|
d) |
The claims against the company not acknowledged as debts
(approximately) |
124.854 |
|
e) |
In respect of the demand raised by the Central Excise Department and
State Excise Department against which the Company has preferred an appeal. |
20.970 |
|
f) |
In respect of disputed income tax and wealth tax matters |
68.529 |
|
g) |
In respect of disputed sales tax matters |
5.000 |
|
h) |
In respect of Municipal Property Tax for the years 1986-87 to 1994-95
against which the company has filed an appeal in court and the said court has
issued stay order |
0.510 |
|
i) |
In respect of Excise Duty Refund at |
74.981 |
Bankers Charges
Report as per Registry
|
This form is for |
Modification of
charge |
|
Charge
identification number of the modified |
90103281 |
|
Corporate
identity number of the company |
U24231GJ1991PLC015132 |
|
Name of the
company |
CADILA
PHARMACEUTICALS LIMITED |
|
Address of the registered
office or of the principal place of
business in |
Cadila Corporate Campus, Sarkhej
- |
|
Type of charge |
Immovable
Property |
|
Particular of
charge holder |
Bank of |
|
Email |
|
|
Nature of
description of the instrument creating or modifying the charge |
As per the instrument
of extension cum creation relating to deposit of title deeds by constructive
delivery as well as deposit of original title deeds executed on 26/05/2010 |
|
Date of
instrument Creating the charge |
26.05.2010 |
|
Amount secured by
the charge |
Rs.5030.000
Millions |
|
Brief particulars
of the principal terms an conditions and extent and operation of the charge |
Rate of Interest Cbi-bplr-2% i.e.
10% p.a.(fresh corporate loan of Rs. 400.000 Millions ) Other joint
charge holders remaining unchanged. Terms of
Repayment CBI (fresh
corporate loan of Rs. 400.000 Millions ) - sixteen quarterly installments
after a moratorium of two years. Others joint
charge holders remaining unchanged. Margin CBI-nil Others joint
charge holders remaining unchanged. Extent and
Operation of the charge First mortgage
and pari passu charge basis to term loan lenders aggregating to Rs. 3230.000
Millions and second mortgage and pari
passu charge basis to bob consortium member banks aggregating to Rs. 1800.000
Millions on the properties fully
described in the second schedule. Thus, making the aggregate credit
facilities to Rs. 5030.000 Millions . |
|
Date of latest
modification prior to the present modification |
11.12.2009 |
|
Particulars of
the present modification |
(I) The Charge
Has Been Modified So As To Include Fresh Corporate Loan Sanctioned By The
Central Bank Of India Amounting To Rs. 400.000 Millions Making Aggregate Credit Facilities To Rs.
5030.000 Millions . (Ii) Extension Of
Pari Passu Charge By Way Of Inclusion Of Immoveable Properties Situated At
Ankleshwar As Security To Existing Charge Holders. |
Fixed
Assets:
Ř
Ř
Ř
Building
Ř
Plant and Machinery
Ř
Furniture and Fixture
Ř
Office Equipments
Ř
Vehicles
Ř
Live Stock
AS PER WEB SITE
DETAILS:
Profile:
Subject is one of the largest privately held pharmaceutical
companies in
The company has one of the best Research and Development (R
and D) setups in
Subject is the first Indian company to get
The company has state-of-the-art manufacturing facilities
conforming to the most stringent international cGMP norms vis-ŕ-vis WHO-GMP,
WHO, Geneva (GDF site for Anti- TB), TGA Australia (PIC/S), USFDA, UK- MHRA,
MCC-South Africa, ISO 9001 and ISO 14001. Spread over hundred acres of land,
Subject manufacturing facility at Dholka is the cynosure of all eyes, well
equipped with world-class production facilities. The company’s two API units at
Ankleshwar manufacture a wide-range of APIs and intermediates including three
USFDA certified products. The manufacturing facility at Samba, near
A responsible corporate citizen conscious of its duty towards various sections of the society; Cadila Pharmaceuticals nurtures young talents; runs an ultra-modern charitable hospital in a remote area with facilities like Telemedicine in association with Apollo Ahmedabad; works closely with NGOs by way of assistance and support for mid-day meal programmes, among other initiatives.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government official
or a family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.13 |
|
|
1 |
Rs.71.05 |
|
Euro |
1 |
Rs.59.10 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
8 |
|
--PROFITABILIRY |
1~10 |
8 |
|
--LIQUIDITY |
1~10 |
8 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
8 |
|
--CREDIT LINES |
1~10 |
7 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
64 |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.